Anti-Interleukin-12/23-Antikörper bei Colitis ulcerosa

被引：0
|
作者：
Manfred Gross
机构：
[1] Internistische Klinik München Süd,
来源：
Gastro-News | 2020年 / 7卷 / 2期
关键词：
D O I：
10.1007/s15036-020-0275-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：18 / 21
页数：3
相关论文
共 50 条
  • [41] Efficacy and Safety of Interleukin-12, 23 Inhibitors vs Interleukin-23 inhibitors for Moderate to Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis
    Pasam, Ravi Teja
    Gautam, Misha
    Venugopalan, Sruthi
    Mohan, Babu
    Navaneethan, Udaykumar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S833 - S834
  • [42] Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice
    Elson, Charles O.
    Cong, Yingzi
    Weaver, Casey T.
    Schoeb, Trenton R.
    McClanahan, Terrill K.
    Fick, Robert B.
    Kastelein, Robert A.
    GASTROENTEROLOGY, 2007, 132 (07) : 2359 - 2370
  • [43] Irsogladine Maleate Prevents Colitis in Interleukin-10 Gene-Deficient Mice by Reducing Interleukin-12 and-23 Production
    Nakagawa, Tomoo
    Katsuno, Tatsuro
    Noguchi, Yoshiko
    Mandai, Yasushi
    Yoshihama, Sayuri
    Saito, Keiko
    Maruoka, Daisuke
    Matsumura, Tomoaki
    Arai, Makoto
    Yokosuka, Osamu
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (11) : 1681 - 1688
  • [44] Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis
    Gandhi, Mona
    Alwawi, Eihab
    Gordon, Kenneth B.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2010, 29 (01) : 48 - 52
  • [45] Einfluss der Anti-TNF-α-Antikörper-Therapie auf Hospitalisation, Operationshäufigkeit und Mortalität bei CED-PatientenImpact of anti-TNF-α antibody therapy on hospitalization, frequency of operations and mortality in IBD patients
    E. Jehle
    coloproctology, 2019, 41 (1) : 46 - 48
  • [46] Anti-IL-7 receptor plus anti-IL12/23 combination induces complete histological normalization in chronic colitis
    Lyssia, B.
    Caroline, M.
    Aurore, M.
    Kevin, B.
    Julien, T.
    Sabrina, P.
    Marion, D.
    Isabelle, G.
    Poirier, N.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i139 - i139
  • [47] A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and-23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis
    Vollmer, Timothy L.
    Wynn, Daniel R.
    Alam, M. Shamsul
    Valdes, Joaquin
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (02) : 181 - 191
  • [48] Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice
    Fuss, IJ
    Marth, T
    Neurath, MF
    Pearlstein, GR
    Jain, A
    Strober, W
    GASTROENTEROLOGY, 1999, 117 (05) : 1078 - 1088
  • [49] Anti-interleukin 12 antibody prevents colitis in a murine T cell transfer model of inflammatory bowel disease
    Singh, B
    Powrie, F
    BRITISH JOURNAL OF SURGERY, 2003, 90 (05) : 637 - 638
  • [50] Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients
    Ferrito, M.
    Cincinelli, G.
    Manara, M.
    Di Taranto, R.
    Favalli, E. G.
    Caporali, R.
    REUMATISMO, 2023, 75 (02) : 76 - 85
12345